In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Kyverna Therapeutics, Inc., with a price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors including the promising interim Phase 2 data for Kyverna Therapeutics’ KYV-101 in treating generalized myasthenia gravis (gMG). The data revealed significant clinical improvements, with all patients showing meaningful reductions in MG-ADL, QMG, and MGC scores. These results, achieved in a heavily pretreated population, underscore the potential of KYV-101 to transform the treatment landscape for gMG.
Furthermore, the safety profile of KYV-101 remains favorable, with no high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity observed. The elimination of the need for chronic immunosuppressants and high-dose steroids further enhances its appeal. With the Phase 2/3 registration study on track to begin by the end of 2025, Ulz’s confidence in the stock is bolstered by the clear path to market and alignment with the FDA.
Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Kyverna Therapeutics, Inc., and Rhythm Pharmaceuticals. According to TipRanks, Ulz has an average return of 5.5% and a 44.97% success rate on recommended stocks.
In another report released today, Wells Fargo also reiterated a Buy rating on the stock with a $31.00 price target.